Dipeptidyl-peptidaseIV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Journal of Diabetes Investigation

Volumn 3, Issue 6, 2012, Pages 498-502

  Senmaru, Takafumi ^a   Fukui, Michiaki ^a   Kobayashi, Kanae ^a   Iwase, Hiroya ^a   Inada, Shinobu ^a   Okada, Hiroshi ^a   Asano, Mai ^a   Yamazaki, Masahiro ^a   Hasegawa, Goji ^a   Nakamura, Naoto ^a   Iwasaki, Masahiro ^b   Yabe, Daisuke ^c   Kurose, Takeshi ^b,c   Seino, Yutaka ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Metab and Clin Nutr Natl C   (Japan)

^c KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Dipeptidyl peptidaseIV inhibitor; Eicosapentaenoic acid; Glucagon like peptide 1

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; ICOSAPENTAENOIC ACID; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT RESPONSE;

EID: 84871645132     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2012.00220.x     Document Type: Article

References (25)

1. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormons: similarities and differences. J Diabetes Invest 2010; 1: 9-23.
2. Ahren B. GLP-1 and extra-islet effects. Horm Metab Res 2004; 36: 842-845.
3. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304-311.
4. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type2 diabetic patients. Diabetes Care 1999; 22: 1137-1143.
5. Brubaker PL. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 2006; 1070: 10-26.
6. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005; 11: 90-94.
7. Morishita M, Tanaka T, Shida T, et al. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release 2008; 132: 99-104.
8. Lands WE, Morris A, Libelt B. Quantitative effects of dietary polyunsaturated fats on the composition of fatty acids in rat tissues. Lipids 1990; 25: 505-516.
9. Sekikawa A, Curb JD, Ueshima H, et al. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 2008; 52: 417-424.
10. von Schacky C. n-3 fatty acids and the prevention of coronary atherosclerosis. Am J Clin Nutr 2000; 71: 224S-227S.
11. Bhatnagar D, Durrington PN. Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract 2003; 57: 305-314.
12. Ueeda M, Doumei T, Takaya Y, et al. Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J 2008; 72: 1836-843.
13. Feskens EJ, Bowles CH, Kromhout D. Inverse association between fish intake and risk of glucose intolerance in normoglycemic elderly men and women. Diabetes Care 1991; 14: 935-941.
14. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995; 18: 1104-1112.
15. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl 1): S5-20.
17. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212-228.
18. Yanagisawa N, Shimada K, Miyazaki T, et al. Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. J Atheroscler Thromb 2010; 17: 285-294.
19. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type2 diabetes. Diabetes Res Clin Pract 2008; 79: 291-298.
20. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
21. Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type2 diabetes. Diabetes Res Clin Pract 2011; 95: e20-e21.
22. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type2 diabetes: a 54-week study. Curr Mel Res Opin 2009; 25: 569-583.
23. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556-1568.
24. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
25. Okubo H, Sasaki S, Rafamantanantsoa HH, et al. Validation of self-reported energy intake by a self-administered diet history questionnaire using the doubly labeled water method in 140 Japanese adults. Eur J Clin Nutr 2008; 62: 1343-1350.